Back

Can we predict the effect of antiarrhythmic pharmacotherapy in atrial fibrillation and metabolic syndrome patients: focus on galectin-3

29 August 2016 (14:00 - 18:00)
Organised by:
Congress Presentation Part of: Poster session 5 - Mechanism of arrhythmia in atrial fibrillation . New data on remodelling biomarkers and anti-arrhythmic drugs Atrial fibrillation (AF) ESC Premium Access ESC Congress 2016

About the speaker

Photo
Assistant Professor Valery Ionin

Saint Petersburg First Pavlov State Medical University, Saint Petersburg (Russian Federation)

28 More presentations in this session

Presentation thumbnail
Doctor M. Manninger (Graz, AT)
Abstract Slides
Presentation thumbnail
Doctor J. Diness (Frederiksberg, DK)
Abstract
Presentation thumbnail
Doctor A. Romanov (Novosibirsk, RU)
Abstract
Presentation thumbnail
Doctor H. Nakamura (Sagamihara, JP)
Abstract Slides
Presentation thumbnail
Professor C. Falcone (Pavia, IT)

Access the full session

Session thumbnail
Poster session 5 - Mechanism of arrhythmia in atrial fibrillation . New data on remodelling biomarkers and anti-arrhythmic drugs

The Event

Event poster

ESC Congress 2016

29 August 2016 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Galectin-3 predicts the risk of ventricular tachycardia in ischemic heart failure patients with implantable cardioverter-defibrillator
30 June 2021
thumbnail
Congress Presentation
Structural remodeling and left atrial fibrosis in patients with atrial fibrillation and metabolic syndrome
30 August 2025
thumbnail
Congress Session
EHRA Consensus Paper on Antiarrhythmic Drugs (AADs)
30 March 2025
thumbnail
Congress Presentation
Influence of therapy in patients with CAD and type 2 diabetes on inflamation biomarkers P-selectin and Galectin-3 changes
20 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources